Literature DB >> 4034237

Immunopathology of Schistosoma japonicum infection in athymic mice.

A W Cheever, J E Byram, F von Lichtenberg.   

Abstract

Athymic (nu/nu) mice and heterozygous littermate controls (nu/+) were examined 7 and 10 weeks after infection with 10 cercariae of Schistosoma japonicum. Schistosome infection developed normally in both groups of mice and eggs were produced in normal numbers. Nu/nu mice developed small circumoval granulomas with minimal fibrosis while nu/+ mice developed large fibrotic granulomas. Unlike the mononuclear responses to S. mansoni eggs at 7 weeks, those to S. japonicum often were abscess like with narrow rims of liver cell necrosis or microvesicular fatty change. However, evolving granulomas in nu/+ mice were enriched with eosinophils, epithelioid macrophages, immature granulocytes and plasma cells, all scarce in the corresponding nu/nu lesions as were fibroblasts and collagen fibres, thus accounting for their smaller mean size and better healing. Our aggregate evidence shows that normal granuloma formation and cellularity in S. japonicum infection is controlled by T-cells as is the case for S. mansoni, and not by antibodies or immune complexes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4034237     DOI: 10.1111/j.1365-3024.1985.tb00085.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  11 in total

1.  Eosinophil chemotactic lymphokine produced by egg-associated granulomas in murine schistosomiasis japonicum.

Authors:  M Owhashi; H Maruyama; Y Nawa
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

2.  Inhibition of immediate and Arthus responses to schistosome egg antigens by T cells from Schistosoma japonicum-infected mice.

Authors:  A B Stavitsky; G R Olds
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

3.  Schistosoma japonicum egg antigen-specific T cell lines in man. Induction of helper and suppressor T cell lines and clones in vitro in a patient with chronic schistosomiasis japonica.

Authors:  N Ohta; T Itagaki; M Minai; K Hirayama; Y Hosaka
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

4.  HLA-DQ-controlled T cell response to soluble egg antigen of Schistosoma japonicum in humans.

Authors:  N Ohta; T Edahiro; A Ishii; M Yasukawa; Y Hosaka
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

5.  Dynamic analysis of splenic Th1 and Th2 lymphocyte functions in mice infected with Schistosoma japonicum.

Authors:  Y H Xu; J Macedonia; A Sher; E Pearce; A W Cheever
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

6.  Granulocyte-macrophage colony-stimulating factor enhances the production of eosinophil chemotactic lymphokine by egg-associated granulomas of Schistosoma japonicum-infected mice.

Authors:  M Owhashi; H Maruyama; Y Nawa
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

7.  Exogenous bone morphogenetic protein-7 reduces hepatic fibrosis in Schistosoma japonicum-infected mice via transforming growth factor-β/Smad signaling.

Authors:  Bo-Lin Chen; Jie Peng; Qing-Fu Li; Min Yang; Yuan Wang; Wei Chen
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

8.  Regulation of the human T-cell response to Schistosoma japonicum egg antigen by concomitant cellular and humoral mechanisms in vitro.

Authors:  N Ohta; H Asahi; Y Hosaka; M Minai; A Ishii
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

9.  Mechanisms of in vivo modulation of granulomatous inflammation in murine schistosomiasis japonicum.

Authors:  G R Olds; A B Stavitsky
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

10.  Induction of experimental murine granuloma formation against Schistosoma japonicum eggs produced by in vitro ova deposition, in vitro tissue extraction, or lyophilization.

Authors:  M Hirata; M Takushima; M Kage; T Fukuma
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.